InternaView membership options
[Comment] Semaglutide for Alzheimer's disease after evoke and evoke+
VIP articleGLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee osteoarthritis, and metabolic dysfunction-associated steatohepatitis.1–4 Evidence in CNS disorders is less consistent, with
ME
MedScopeGlobal Editorial
May 29, 2026
InternaVIP
Evidence-based clinical briefing
[Comment] Semaglutide for Alzheimer's
MedScope VIP
This article is reserved for VIP subscribers. Upgrade for full access, an ad-free reading experience, and priority clinical alerts.
Doporučený obsah
Články
- Mapping the intellectual structure and emerging trends of neurophobia research in health professions education
- Mapping the intellectual structure and emerging trends of neurophobia research in health professions education
- Synergistic Renoprotective Effects of Moderate-Intensity Resistance Training and Vitamin D Supplementation on a Type 2 Diabetic Nephropathy Rat Model
- Diagnostika a screening u nejčastějších symptomů
Studie
- RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings
- Upskilling Rheumatology Occupational Therapists in Work Rehabilitation: An Evaluation of a Job Retention Vocational Rehabilitation Training Course (the Workwell Trial)
- Satisfaction with telemedicine versus in-person visits in rheumatology: a noninferiority randomised controlled trial